大剂量双联疗法治疗幽门螺杆菌随机对照试验的Meta分析-现代医学

大剂量双联疗法治疗幽门螺杆菌随机对照试验的Meta分析

单位：1. 长沙市中心医院消化内科, 湖南长沙 410004;
2. 中南大学湘雅医院血液内科, 湖南长沙 410008

分类号：R573.9

出版年·卷·期（页码）：2022·50·第二期（192-200）

摘要：

目的:评价大剂量双联疗法作为一线方案治疗幽门螺杆菌的有效性和安全性。方法:检索PubMed、Cochrane Library、Embase、万方数据库、维普、中国知网(CNKI),纳入符合要求的随机对照试验。采用STATA 12.0版本进行统计学分析,主要结果是幽门螺杆菌的根除率,次要结果是不良事件发生率和患者的依从性。结果:共有9个随机对照试验2 519例患者符合纳入条件。大剂量双联疗法的根除率(OR=1.12,95%CI 0.77~1.64,P=0.555)和依从性(OR=1.20,95%CI 0.71~2.03,P=0.487)与目前一线推荐方案如三联疗法、含铋剂四联疗法的差异无统计学意义。大剂量双联疗法能明显降低不良事件的发生率,差异具有统计学意义(OR=0.36,95%CI 0.22~0.59,P<0.001)。通过敏感性分析,确定这一结果是稳定可靠的。结论:大剂量双联疗法和目前一线治疗方案相比,具有相同的疗效和依从性,并能减少不良事件的发生。

Objective:To evaluate the effectiveness and safety of high-dose dual therapy (HDDT) as a first-line treatment for Helicobacter pylori.Methods:The major databases of PubMed,Cochrane Library,Embase,Wanfang Data,VIP and CNKI were searched.Randomized controlled trials that meet the requirements were included.Using STATA version 12.0 for statistical analysis,the main result was the eradication rate of Helicobacter pylori.The secondary results were the incidence of sad effects and compliance.Results:A total of 2 519 patients from 9 randomized controlled trials were eligible for inclusion.The eradication rate of HDDT (OR=1.12,95%CI0.77-1.64,P=0.555) and compliance (OR=1.20,95%CI 0.71-2.03,P=0.487) were not significantly different from the current first-line recommended regimens such as triple therapy and bismuth quadruple therapy.HDDT can significantly reduce the incidence of sad effects (OR=0.36,95%CI0.22-0.59,P<0.001).Sensitivity analysis confirmed that the result was robust and reliable.Conclusion:Compared with the current first-line therapies,HDDT program has the same efficacy and compliance,and show few sad effects.

参考文献：

[1] ZHANG M,ZHOU Y Z,LI X Y,et al.Seroepidemiology of Helicobacter pylori infection in elderly people in the Beijing region,China[J].World J Gastroenterol,2014,20(13):3635-3639.
[2] NAGY P,JOHANSSON S,MOLLOY-BLAND M.Systematic review of time trends in the prevalence of Helicobacterpylori infection in China and the USA[J].Gut Pathog,2016,8:8.
[3] BLASER M J,ATHERTON J C.Helicobacter pylori persistence:biology and disease[J].J Clin Invest,2004,113(3):321-333.
[4] VAKIL N,MEGRAUD F.Eradication therapy for Helicobacter pylori[J].Gastroenterology,2007,133(3):985-1001.
[5] FUKASE K,KATO M,KIKUCHI S,et al.Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer:an open-label,randomised controlled trial[J].Lancet,2008,372(9636):392-397.
[6] MALFERTHEINER P,MEGROUD F,O'MORAIN C A,et al.Management of Helicobacter pylori infection——the Maastricht IV/Florence Consensus Report[J].Gut,2012,61(5):646-664.
[7] BANIC M,FRANCESCHI F,BABIC Z,et al.Extragastric manifestations of Helicobacter pylori infection[J].Helicobacter,2012,17(Suppl 1):49-55.
[8] Schistosomes,liver flukes and Helicobacter pylori.IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.Lyon,7-14 June 1994[J].IARC Monogr Eval Carcinog Risks Hum,1994,61:1-241.
[9] SUGANO K,TACK J,KUIPERS E J,et al.Kyoto global consensus report on Helicobacter pylori gastritis[J].Gut,2015,64(9):1353-1367.
[10] GLUPCZYNSKI Y,MEGRAUD F,LOPEZ-BREA M,et al.European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori[J].Eur J Clin Microbiol Infect Dis,2001,20(11):820-823.
[11] GRAHAM D Y,SHIOTANI A.New concepts of resistance in the treatment of Helicobacter pylori infections[J].Nat Clin Pract Gastroenterol Hepatol,2008,5(6):321-331.
[12] FALLONE C A,CHIBA N,VAN ZANTEN S V,et al.The toronto consensus for the treatment of Helicobacter pylori infection in adults[J].Gastroenterology,2016,151(1):51-69 e14.
[13] CHEY W D,LRONTIADIS G I,HOWDEN C W,et al.ACG Clinical Guideline:Treatment of Helicobacter pylori Infection[J].Am J Gastroenterol,2017,112(2):212-239.
[14] SONG Z,ZHOU L,XUE Y,et al.A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication:a randomized trial[J].Helicobacter,2020,25(6):e12762.
[15] HWONG-RUEY LEOW A,CHANG J V,GOH K L.Searching for an optimal therapy for H pylori eradication:High-dose proton-pump inhibitor dual therapy with amoxicillin vs.standard triple therapy for 14 days[J].Helicobacter,2020,25(5):e12723.
[16] YANG J,ZHANG Y,FAN L,et al.Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori[J].Am J Gastroenterol,2019,114(3):437-445.
[17] LEOW A H R,GOH K L.14-day high-dose dual therapy is equally as good as 14-day clarithromycin based standard triple therapy in first line H.pylori eradication treatment[J].J Gastroentero Hepatol,2018,33:363.
[18] 高采平,肖讯,刘培曦,等.大剂量阿莫西林/埃索美拉唑二联方案根除幽门螺杆菌[J].世界华人消化杂志,2018,26(6):353-359.
[19] SAPMAZ F,KALKAN I H,ATASOY P,et al.A non-inferiority study:modified dual therapy consisting higher doses of rabeprazole is as successful as standard quadruple therapy in eradication of Helicobacter pylori[J].Am J Ther,2017,24(4):e393-e398.
[20] HU J L,YANG J,ZHOU Y B,et al.Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China[J].Saudi J Gastroenterol,2017,23(5):275-280.
[21] YANG J C,LIN C J,WANG H L,et al.High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection[J].Clin Gastroenterol hepatol,2015,13(5):895-905.
[22] KIM S Y,JUNG S W,KIM J H,et al.Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea[J].Br J clin Pharmacol,2012,73(1):140-143.
[23] MEGRAUD F,COENEN S,VERSPORTEN A,et al.Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption[J].Gut,2013,62(1):34-42.
[24] RAHMAN R,ASOMBANG A W,IBDAH J A.Characteristics of gastric cancer in Asia[J].World J Gastroenterol,2014,20(16):4483-4490.
[25] GAO W,CHENG H,HU F,et al.The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing,China[J].Helicobacter,2010,15(5):460-466.
[26] ZHANG Y X,ZHOU L Y,SONG Z Q,et al.Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing:a prospective serial study[J].World J Gastroenterol,2015,21(9):2786-2792.
[27] HU Y,ZHU Y,LU N H.Primary antibiotic resistance of Helicobacter pylori in China[J].Dig Dis Sci,2017,62(5):1146-1154.
[28] SAVOLDI A,CARRARA E,GRAHAM D Y,et al.Prevalence of Antibiotic Resistance in Helicobacter pylori:A Systematic Review and Meta-analysis in World Health Organization Regions[J].Gastroenterology,2018,155(5):1372-1382 e1317.
[29] UNGE P,GAD A,GNARPE H,et al.Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis?A pilot study[J].Scand J Gastroenterol,1989,167:49-54.
[30] WONG B C,XIAO S D,HU F L,et al.Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer:an Asian multicentre double-blind randomized placebo controlled study[J].Aliment PharmacolTher,2000,14(2):217-224.
[31] BAYERDORFFER E,MIEHLKE S,MANNES G A,et al.Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers[J].Gastroenterology,1995,108(5):1412-1417.
[32] SCOTT D,WEEKS D,MELCHERS K,et al.The life and death of Helicobacter pylori[J].Gut,1998,43(Suppl 1):S56-60.
[33] ERAH P O,GODDARD A F,BARRETT D A,et al.The stability of amoxycillin,clarithromycin and metronidazole in gastric juice:relevance to the treatment of Helicobacter pylori infection[J].J Antimicrob Chemother,1997,39(1):5-12.
[34] ANDERSSON T,HOLMBERG J,ROHSS K,et al.Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors,omeprazole,lansoprazole,and pantoprazole[J].Br J Clin Pharmacol,1998,45(4):369-375.
[35] FURUTA T,SHIRAI N,TAKASHIMA M,et al.Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin[J].Pharmacogenetics,2001,11(4):341-348.
[36] YUN J,WU Z,QI G,et al.The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection[J].Expert RevGastroenterolHepatol,2021,15(2):149-157.
[37] GRAHAM D Y,LU H,YAMAOKA Y.A report card to grade Helicobacter pylori therapy[J].Helicobacter,2007,12(4):275-278.
[38] GRAHAM D Y,FISCHBACH L.Helicobacter pylori treatment in the era of increasing antibiotic resistance[J].Gut,2010,59(8):1143-1153.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录